NBIX - Earnings call transcript Q2 2022 | Neurocrine Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone. And welcome to today's Neurocrine Biosciences Reports Second Quarter Results [Operator Instructions]. Please note today's call may be recorded, and I will be stnading by should you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.

Todd Tushla

operator. you, Thank and call. everyone, our quarter second Good welcome earnings XXXX afternoon, to With Executive Medical our our Gorman, Development and me Kevin are Chief our Chief our Commercial Officer; Business Roberts, Kyle Gano, Benevich, Strategy Chief Eiry Officer; our Eric Chief Officer. Officer; and Chief Officer; Financial Abernethy, Matt

to discussed certain factors differ will and our uncertainties, we call, statements. materially. our SEC and where remarks, try the questions. latest Kevin in encourage making head to we'll forward-looking I'll risk to now everyone's prepared These results our Gorman. risks may review our statements After During be are filings. to I you subject into the turn we'll to Q&A over actual And call get

Kevin Gorman

good afternoon. and you, Thank Todd,

-- had half excellent a outperformance bit good with going the to said, just our us in have take going quarter keep you in QX, give through a to coupled an year. Todd opening a very INGREZZA time first short we're for questions. we more of is our enough in the moment. to I'll Eric QX. detail And your remarks As had

in say to our with about those we adding pleased very grow and compounds addition, action validated two talk continue new in of a bit I'm pipeline, mechanisms psychiatry, Now will to Eiry two.

any study Now this as warrant you've of in not development yield did signal tremor strong seen release, a data time. essential press ET in to further our this seeking enough set our at compound

disappointing, these redeployed. portfolio resources and have will and rapidly rich diversified While be we a

it still XXXX, the transition but much and of disease COVID COVID. the of with larger company are more in I pleased Thankfully, business into I'm We mean all of as see business due stretches the Times to Increased an We still it are dealing usual like clinical patients positive thus behalf performance and turn highly throughout Matt and and we I and I'd pandemic in Now caused resources to death, over year. and now, finally, rarely to businesses. to to I'd endemic that that overall here, is on very say forward move far our severe absences disruptive am situation uncertain, with to of very testing a like society times. please. world. all the we, with for both at this the but proud. that, the continue thin out commercial

Matt Abernethy

of team the QX INGREZZA The afternoon. delivered from capitalizing sales strong quarter, on and Good high in patient second levels the trends million compliance. during new patient $XXX

us, billion half With XXXX our upon now $X.XX far the this billion to INGREZZA first guidance based to behind of annual have we $X.X seen so trends we sales year. the are raising range

of COVID as result As be you sequential expect both growth to cases third consider lower typical quarter the dynamic the summer a acceleration and of we QX, pressure growth.

front, convertible billion we with quarter, maintain financial of to the reduce financial need were able the in during On over and dilution debt XX% to the we $X potential cash. flexibility retire our

Now over Eric. to

Eric Benevich

Matt. Thanks,

commercial initiatives. patient our INGREZZA and record primarily starts. with continues level persistence continued a by QX continuing a strong coupled new for on great rates job was team do performance Our patients, executing of to driven compliance

out the couple the of As the a year, results of that half year. the said, half to incorporates scenarios that through first in a Matt the of play raised given range second we've guidance may

the the treatment our far, relates year. TD. to for campaign, help to Spotlight, factors, of ongoing balance it plan been pleased and we seek the and Thus to campaign called to internal as First, with TD patients their encourage continues advertising we've continue the caregivers through direct-to-consumer response,

about a members trained have field and been expanded been now have of in In the our addition, force for the newest field quarter.

our of expanded we've the As benefit highlighted part to the sales anticipate be tangible latter year. in organization we of before, the

customers, external is Regarding provide an seen variants perspective, psychiatrists continued our for headwinds we've to their half from still COVID telemedicine with being patients. roughly while new of what utilized by

five treatment we the improving I a past are third external dynamics, underdeveloped patients progress, INGREZZA for to slowdown than to This would we continue be TD the Dr. which in low diagnosis new the pattern market bit my help tardive be the still of we're and call rates challenges Therefore, dyskinesia years steady I'll impacted by typically the more to and characterize given less that, in of QX well mostly more to COVID, and Roberts. growth to end the is guidance we've over impacted treatment positioned range seasonal end driving seen launch, the of has softened relative of making QX. the ever by higher US. to range to even the quarter, factors, working telehealth diligently closing, mitigate. higher In colleague, the Over a are and With current which Eiry turn before. rates seasonal a

Eiry Roberts

a We start Thank for from you, on Eric, couple call. remain on everyone and good our track afternoon for treatment Huntington's disease. the submission as sNDA late potential of updates with this of stage the year a later to I'll valbenazine clinical portfolio.

XXXX. our the treatment Crinecerfont data are goal adult addition, potential congenital with for as delivering well, Phase hyperplasia for in line progressing a and of in III In adrenal studies pediatric

Moving a opportunity Phase with I Heptares. announce earlier schizophrenia. treatment to including to with MX clinic, Heptares novel successfully This take the MX/MX II molecule into other the in of teams, both potential a progressing and Neurocrine our their the agonist. stage study, expand work with orthosteric examining future. to for teams we a dual for this NBI-XXX, beyond Sosei the work the to were our in agonists the IND to on is portfolio, into the for franchise the will pleased lead thank schizophrenia which in moment at XXX, enrollment FDA's begin to continue Along And hard want of collaboration agonist muscarinic selective Sosei acceptance the advancing the near clinical molecule recent muscarinic very

development, a will Phase clinically we the approach this about potentially II molecule, both molecules. of I treatment in Phase the XXX, successful, provide mechanism more will initiate evaluation addition action If targets progressing In divulge active that important oral would for a month, which forward But this target first we top parenterally moving NBI-XXX Difficulty]. for already say treatment novel, of for validated depression. the NBI-XXX, [Technical depression. clinical If to in are administered to with mechanism this can been orally we I small has by successful NBI

this essential NBI-XXX signal-seeking was high a NBI-XXX study The doses patient patients the team in in in well address single completed and to I'd study was XX population. the the tolerated with tremor. Now of potential The this signals study like of intent to tolerability determine NBI-XXX of quality, center identify tremor. efficacy NBI-XXX results studied. at of essential of of all

data current However, Based broad it note this with the we evaluate time, is plan line the of statistical further not set is spike-in-wave from tremor. epilepsy on of not top study that by presenting achieve in impact development year-end. of results produced the top the II data beyond future significance. information, data study, at Enrollment this on track failed study line essential during to line NBI-XXX NBI-XXX results Phase do of and complete the results with important efficacy clinical to these intent It in sleep. the this from in top proceed medical and study do to study continuous at conference. we remain to continuing a a with and totality is team The this were negative to the disclose

things Finally, look efforts forward of getting I'd Pharma Corporation DYSVAL to Tanabe approved. the of back to With I'll Kevin. We that, dyskinesia our congratulate Mitsubishi like the in supporting partners their to all valbenazine for treatment for their Japan. tardive in at launch hand

Kevin Gorman

now Eiry. are much, you to questions. ready Thank take very we operator, And

Operator

[Operator first Company. Instructions] with we'll & Phil And to move Nadeau Cowen

Phil Nadeau

two Just us. from

They're impacted QXs for because particularly First, as past. in for results INGREZZA, INGREZZA. seasonal wasn't QX factors other QX -- impressive on because particularly the by as they're the impressive, QX results

did the we're Was or were guess strictly of whether what detail how curious then the the to from new just your generally, mechanism guidance, of put disease, that increase could improve ET. initially guidance, curious channel QX, we data do run It suggest in in And into more can question the into anticipated, is QX the calcium that down T-type your led to in with were issue [recurs], COVID was more and there factors? any compound maybe bottom you patient you on renewed any the that had minds, QX there the simply quarters specific? than or an the with blockers factors think DTC QX. end that this question onetime happen? in I So that in rate? versus So QX your We're and second go whether seasonal does those as strike starts aside us

Matt Abernethy

of handle to one set try and We're first. ET going stick going your question to we're we'll we get questions questions further on into front, as then the first handle to INGREZZA as to

rates. also You're additions very compliance right, and high reflecting quarter, great patient then QX was surprisingly great an new incredibly

inventory flag I'd throughout trajectory fairly We the purchases bulk or additions compliance from items, in came by both of pharmacies. external continued then such patient say nice then also onetime new strong any obviously, quarter. So as a was a beat step-up wouldn't and and any internal was the

was a it straightforward very So clean, quarter.

coming still you to guidance we're about Eric incredible that's his it the feet with growth then around downside in as range, really here. And really dealing out right is mentioned a and the remarks, step now. reflects our a very prepared If COVID environment with of and And COVID. that take specific million dealing think back pretty $XXX

all the I top the think the could end of at some that side. aggregation at bottom the the popping range. up all about And sales regionally expansion we and force disruption range, see end it's on then cause of it

Phil. So hopefully, question, your that addresses

Operator

next our Markets. from Abrahams with take question We'll RBC Brian Capital

Leonid Timashev

to you the you to guess, be just to there or epilepsies? active little Leonid is still discontinue, on is XXX. decision for the And I can guess think it that why back the bit is talk some just a This [across] might endpoints I I view any then want to all more of in might Brian. go that epilepsies able well? this you go about back drug that picture out on epilepsy, data, we it to tease the in was as the or window? at might just you the bigger I therapeutic to where be thinking And as continue as guess look signals bringing you any continue about

Eiry Roberts

couple in a questions there. of So

question, we're between patient essential the CSWS. population, tremor first that think the within and I the you studying epilepsy On if population, look

So very it's a different population.

at. what us around we one think trial from out, as center way about which I it other well the and question, played was the evidence the And the on can other the or and calcium was about hit assessments concordance central [test] not is the that on sufficiently do some directly looked well development. of Also say high negative particular, assessments. but this can believe we was population local data, to the to trial other. had there we the TETRAS And T-type that for a saw I actually in of was you or infer sets were accelerometer quality well the between trial. really a antagonist we on the and hard significance that assessments asked relevance, so context I endpoints it's say I signal tremor, robust in thing Phil that in the the as But it at in was to negative that we answer for ran in to comment not molecules of the trial, results. high single to activity, responsible don't either channel two not was what clinical think will as that a as the statistical trial controlled looked We on the failed the trial, design the It essential

that think forward essential I We'll continue this moving XXX. tremor to the with more a are at set. depth. will clear in it But be not we point data in So for data we was time, evaluate robust

Operator

we'll our with Matteis question And take Stifel. next Paul from

Paul Matteis

that you've Over you've upfront business few the in conservative the past been years, super offered development. just with

there of and the us an given that meaningful if is any incorporate that next. on think thinking do update And INGREZZA, you something also failure transaction given been your this bit that more there's you've a been I ET you consideration CNS your high the whether strength and setbacks, pipeline guess a given could I'm But I program, bigger if maybe the capacity have number little of to see and a just now risk clear is of have we so? of difficult. there give position could wondering year your of over

Kevin Gorman

going I'm put Kyle. that to question to

Kyle Gano

on talked in we've view probability for about success. of versus I the them past, as of this the discovered development Paul, assets, similarly in internally think outset business we firstly, terms

I also from of when think agnostic it structure and add fair that we're view really that's I'd for opportunities that perspective. organizations to strategic things the thinking that all at today. to licensing, about versus we're scope in are that looking And

available I place where pipeline. the in expense stage being issues items commercial, and development. think are higher value, in and we be that think in And either in are CNS our see own their that the those see the extreme continue stage higher I that higher bifurcated terms are are that evaluate earlier to we a to space, would those of assets late science

nutshell, new types development. things possible, as stage and the that I are types see In a much over strategic Phase brought that pipeline to And licensing look deals see at sustain balance that of today, Phase a mid of you the and look it balance if validated assets dozen and are A those the III to we those programs from and in to create those. that in late of when targets are novel. with manage there we time. close, at the we look are This So about at those pipeline on in a front. in as we we you

Operator

We'll take Bank question our of Tazeen from with Ahmad America. next

Tazeen Ahmad

go the quarter the back for I'd the just your to and the of to results So like INGREZZA from view rest year.

five growth you improved on what call, XQ why So had meaningfully wouldn't talked about you several already when know, is you impact, sequential we've you've what, and weeks to. that surges looking into your I and was quarter. a change? expect that that compliance level thoughts about, saying the But cetera. quarter, didn't to know like, et of we've COVID, I don't are the And you gave pretty see time, had been accustomed your would COVID that to were you compliance adamant about great XQ after XQ that which throughout seem But frankly,

for of So this the able year concerned to that part quarter trying what understand I'm you just this of half? or this most half still in to first dynamic you're the about were overcome

Kyle Gano

only front, to longer wouldn't over I it of at clear take call be it's huge a something Just time. the surge compliance periods compliance, a on better really that you of look can

the that that itself on see good changes an to our of rate understanding to staying medicine to don't And and patient looks slight a I of reps, on something think instances large and So couple it respect has into the five patients quarterly would disruption. of weeks really and get rates sight I testament at beginning the COVID-centric we caused we've it's are not say We taking it the of typically refill have sporadic be this some refill something into launch. per in call. medicine on the seen patient to quarter. are level weeks do quarter, what a out that's We of ever a just clear want definitely like. a per look basis that's you And on drives clinicians. a contributions. COVID, doctors, revenue The is in COVID patients since office, thing

to here? but a to you Our look as scenarios them the shoot add high can have balanced really on anything always But could every view with give potential Eric, what we calls, do like. as quarter is as view

Eric Benevich

Maybe just in a bit. chime little to

the a that that then that QX, that of a may But And And lot in Tazeen, recall, new QX number I record. we flagged QX, think You record a that call as said out patient we huge patients on now quarter we set and another QX, into we a had in starts. coming that patient new QX those carried new the in towards QX. results the course. are of starts of of started momentum contributor

saw add now. as have measures large course, got said, really in Matt persistence And changes of a small that As we can up patient -- over base those and in of you really you've ours when when adherence QX. compliance good as is

historically patient slower the So we just as new reasons for the And regards various launch. growth of flag I said of important with years quarter sort has starts of a and the QX would QX an balance that year, have the five contributor. over to been the

sure The investors to for general, in been relatively we quarter launch. that than QX But really whereas expect past. compared so almost phase in early be slower to us. year different And newer factor quarter, don't understand any growth we of been that is strong the a this to make always want has QX COVID has the years a growth

Operator

And we'll Citi. Neena move with to next Bitritto-Garg

Neena Bitritto-Garg

assuming of of the the I like earlier. the talk there of no about quarters just about we wondering just on next you you're and of lower perspective few at XQ growth about reps new a do to year. much from an assuming second little kind was the you range, you last a how the forward? the sales of dollar and moving growth think that it the essentially impact end did little think the seems bit a if should essentially could how impacts know, I talk similar high had bit guidance end, But half level you're Matt, number at

sales to factors the new how understand trying in. just So force

Eric Benevich

was the now the bottom time the issued take beginning guidance. me top the say end what we've year. we and of that step the at let that So back of of at a range guidance our end is And the just range our raised

a the of But on scenario. end good in And half up wanted range by the XXXX. have do feel expect about end make a where second year not very everyone expecting of to to we're so understands we that year. And we've trajectory the sure be thus we the the we been to far we and no-growth

their So that is their get What working hard take first people for get up being of takes said, in a guided to We've and meet hit sales backfills that to for people question, with speed. team. Everyone regards the really to bit going but very in it's the time they're all folks it into was in which and with got experienced to et a little time force. site experience in TD and they've new integrated doesn't of your to we've mean our these is just because externally to LTC of about stride. INGREZZA. cetera, territories, to bit their the customers, hired experienced that neurology really part But

we're start So in doing I everyone from field success, for with our year. set we really based all it's terms relationships, doing latter impact a prior things tangible practices, cetera. in expanded see that et think experience sales a right to on and and of when expansion the more towards to the collaboration, handing off great best part the field we're teamwork of the of team, belief our would terms up customer But be job it sharing

all of things. that. yet degree We So the the we're to but gauge in summary, early are they think making a contribution, right it's doing

Operator

Olson question from Jay And our with next take Oppenheimer. we'll

Jay Olson

other your to programs muscuranic is talk read soon? Karuna XXX about do study the And clinically going what differentiated like you of MX read Can and from EMERGENT-X agonist sort be out selective of Cerevel? from which across KarXT, you expect will

Eiry Roberts

selective beginning rapidly FDA the Phase dose just excited which we're to MX. is patients start point to enrollment finding with us a program, is We're will very a agonist orthosteric be about soon. that And agonist II to you, they study XXX XXX Phase with in of schizophrenia. This remind pleased think our I an and cleared study, the able II be get really to very to

this it go the And into molecule area. is disease so of nature that first to

Cerevel a think in mechanism we direct the modulator versus validation those predict molecules. of muscarinic clearly, by agonist the versus the difficult with the it's both positive to acute I Karuna psychosis. very differentiation nonselective profile But between a a of and right encouraged agonist, by were now MX

We thing progressing us dose that finding in For important and area, us, this a the some get possible answer as to Phase to believe it's the on disease going study us II study. be designed we'll enroll questions is allow most key rapidly well that for as to will study.

Operator

Carter to Gould And we'll move Barclays. next with

Carter Gould

what do been going And I evolving if to come you wanted the that, how on to the think to a expanding the how us any if you that help over could contributing see forward? -- kind it's campaign, to just you that's I want And there? year. there's thought to DTC of extent that or magnitude now

Eric Benevich

patients of it on in we're We're and campaign, we looking expectations really it's and to with partner rates assess population. road, that of at going down remarks, our company. the receive I we indicators terms of end towards people reevaluate pleased we're in high key campaign. to pleased it's get starts. DTC and views performance patient the a the for look the return downloads care seen XXXX. page to course, of new like through least meeting at Web little for with the year my And when behaviors the visiting of as and looks investment we're continue plan site, And prepared DTC in target Ultimately, and mentioned the continue in contributor consistently what the the information further people important we'll the from lots the of an We've and registering

given of et to of to seen our got any of field really appropriate. what's expanded with a invest along it's headroom how But are cetera. In lot we've with of contributor it and this as terms contributor an market And we force, different terms going together strong a got is expectation we've important the guidance that all and see these in initiatives that things marketing year, of other our of think of time. programs we continue the growth lot success, to much our we're at obviously, a opportunity driving here this we've raising the

Operator

Anupam JPMorgan. question Rama with is from Next

Anupam Rama

I'm year which I R&D program the opening and really in missed you driving little maybe could Matt, what's sorry expense if for specifically? increase a But bit highlight and about this comments. your that the

Matt Abernethy

R&D million that [of muscarinic $XX Sosei is with it's the expense, associated program. spend], milestone On the Heptares

So of we triggered that the and milestone II. with IND initiation of the Phase the acceptance

it's purely related expense. So a milestone

Operator

next move Skorney we'll And Brian to Baird. with

Brian Skorney

to So BMAT this from needs be that would Deutetrabenazine, drawing from, how switching in much market a will think based on the was thoughts if understand to front. you any an drive? I naive know given sNDA the might patients any patients? will do you started launch on about growth? would this work how where I it's hoping of wondered the current get targeting be Do a I year and just ahead think or you it what before line. trying to to you Just time accelerate this market anticipate inflection

Eric Benevich

the market. Well, yes, There's planning. have One data. our prescribing to looks about this our about we're very is is but pretty we along that far TD like, label we're to the Obviously, this excited to labeling completely incremental very, way INGREZZA. certainly off very little in We're opportunity. of excited the about think what see

patients for choreiform a movements. differentiated suffering are that Huntington's And from that INGREZZA treatment offers think disease so option we with

with treated know, reasons. inhibitors various may are VMATX majority you chorea that As have for the patients not of Huntington's

tap are Certainly, market chorea the really with some there current growth population. that And opportunity treated majority don't may to patient is will as opportunity. primarily a to -- untreated so to INGREZZA patients that treatments into but switching choose switch a our that we of view this be

various patients in to hopefully make treated have most will for translate TD us lends the that we majority that those aim attributes product prescribed we the market. in Our into reasons. being And that think itself really HD the preferred is of terms address of the product well profile aren't that TD in well

forward looking we're that year. next to So opportunity

Operator

Goldman next Sachs. with Chris Shibutani move we'll to And

Chris Shibutani

especially wanted for exposures your quarter. to and bigger implications strong about of on Congratulations in potential on companies, thoughts innovation, potential versus and what share ask, would particular, a that view drugs, pharmaceutical this implications you I across about Kevin, involve Medicare talk from might remind that's to commercial small in on your discussions very also the from for strategy. us point are people picture on is thinking companies, come negotiations, of the any Could week, your the specifically? different point, that topic Neurocrine a different pricing drug biologics, how to pipeline groups, types molecule be vantage certain impact feel payer you investing from legislation

Kevin Gorman

little important timely a parts and very There's question, now. of place timely. it's lot Chris, a taking maybe too right are a moving that

the suggest, as as read early team reports press as to You own D.C. our this morning things be Washington, in appear as well very much flux.

wait whatever the is the talking be will or will and out. when be term to thoughts about now, As see I speculate our don't how clarity, such, want we it that in that up bill. speculate there is giving be and would specific on about impact that. or and we'll turns still that to ends be on so sorry premature ultimately the sausage for talk company me to the appears this on we made I'm But think I

Operator

next We'll question from Blair. take our Minter Myles with William

Myles Minter

the Just do that within maybe a to of to study the II on Phase arm? mechanism. therapy an XXX, cardiovascular planning And study are monitoring run you plan Phase alongside you do II adjunctive effects separate study,

Eiry Roberts

current focused understanding Phase for We psychosis. responsiveness on study acute The in study. therapy plans don't is have dose the in II current adjunctive

study measures information the cardiovascular from cardiovascular looks separate We not the what planning We will safety have are like clinic study. agonist the current really from the extensive a is then we assessment. there intend including study, to -- throughout But time, at this obviously selective the see proceed in and molecules have MX before. to that given been rather the ongoing decide a Phase than that II this how

Operator

And next with Danielle to Brill we'll move Raymond James.

Danielle Brill

is a it shifted prescribing I differently. little new has guess, still psychiatrists, a of maybe hires. have XX% contribution XX% the just quick follow-up from ask And the neurologists? mix or at But I'll about the sales all I contribution

Eric Benevich

seeing, prescribers attributing we signs the is recently was to are still the and and everyone that distinct were Like fact that it I would an be the field seeing the efforts. terms team deployed general, to an from But we're LTC events. they've deeper to what caution in of of activity I neurology deployment Those And the previously. So to promotional untapped the for strong QX that with we quarter in us three similar deployed. positive that psychiatry go the field market mix able response essentially a simultaneous pretty of of been team. to But very ago. to the in ultimately, expect both the we expansion and going expanded is course, sales do essentially we're sales segments said,

be more opportunity so year and shaping to are how more support to to this we'll up. we we when we're detail be customers. about the organization of able terms get things that in reach provide, I But further along think, And able with field a the in very optimistic of larger have

Operator

next We'll Chico question from take our Laura Wedbush. with

Laura Chico

field may I'm of to the just this quarters be in not rate run And exclusivity recent INGREZZA? might INGREZZA, for the do also directionally think guess only runway have force, point? how how trying I you I to terms the thinking but understand to now you at the guess adjustments outlook back following about peak about how changed in the

Matt Abernethy

Laura, this is Matt.

the the of mid-XXXXs, strength space feel we we’ll our that. patent good confident have very front, feel we exclusivity and very about into that protection the with On

how of not think As you've commentary in an what really just market. given this it seen that peak we dyskinesia far have relates the the year tardive reflects But the we've will I any still the be. think And have we only those opportunity associated we diagnosis that half much growth the there's of so to peak, and telehealth to XX% point. at of even market as patients of still continuing be think a We an treated untapped, growth XX%. being where is reflective this environment only look received is and this at with

So Eric, there? to add anything

Eric Benevich

patients undiagnosed, are VMATX in thing diagnosed the patients half only that point with is addition being to offered a of when they're The TD, the that I not as other yet out still time inhibitor. about majority would

sure made amount there's they in offered of effective of still terms be And treatment. significant with get diagnosed progress get TD so a to people that making and

would we've system, we're the tremendous point that both in of nurse TD. well, physician talking and somewhat and practitioners They're providers assistance about are now psychiatry, diagnosing growth and advanced last as other here. to it I practice in and and in thing relates of The is that out, seen care question the number the important neurology part an treating

more organization, able reach expansion care important With of of we're our educate to the field be providers. those going health and to

help like patients even so to long years possible. to launch, there's and in many And the TD of we're develop go into the feel as a continuing five market to though we way terms as

Operator

We'll with Duncan from Charles Cantor take question our Fitzgerald. next

Unidentified Analyst

for line the on Charles. [Avi] It's

depth past the So quarter's amongst current we base, were wondering if acceleration if was prescribers? prescriber in of or more driven this by prescribers performance an primarily greater I growth from new was guess, it or

Matt Abernethy

that and did with opportunity [riders] as quarter on We as the new the call of deeper see clinicians. this neurology. of and we lot in new to dyskinesia a existing is with segment really is more development well the said in focus we long INGREZZA left we've LTC, market are with going have starting tardive What a

in say, our from would scripts by So nice base. we the of going majority came existing biggest expect have will enlarge, that over prescribers time, But a deeper. we increase prescriber I'd

Eric Benevich

Matt We'll new that movement the the calling market of patients course, it's appropriate ultimately, the within LTC. most treatment is the that, said, And other drug are as have tackle make TD new and not of over and continue to segments to to Just to added breadth already on of new between especially we're on practices as not time, diagnosed. that tack disorders just And when TD about so on. like patient our prescribers TD offer see the new helping distinction it's the continue people recognize But get it's writers, we INGREZZA effective with to focus induced increasing depth to we important. the business about much but starts.

Operator

And Markets. BMO next Seigerman with we'll Capital Evan move to

Unidentified Analyst

Keith Evan. on here for

if end, DTC revenue cadence? wondering on or impact inventory And provide recognition program to the channel INGREZZA Just could does that then dynamics you color any the build?

Matt Abernethy

I been at that and very on inventory a nothing to believe I front, on there, So flag the position, stable inventory commented we've so earlier.

on advertising quarter. So we're metrics. successful the point DTC And direct-to-consumer Eric center what the very all at were as towards with are the the this fairly campaign, Web clean call mentioned a indicators results pointing all this in program seeing metrics site and

And say performing our expectations. so at it's would I

Eric Benevich

our and we dynamics? that prescriptions in is an from other perspective. we It's channel. needs No, it pharmacy limited that and written a INGREZZA limited doesn't. are are only flexibility DTC pharmacy impact Ultimately, large the it Keith, think But have filled going network. channel that The to of any terms access through get for I that network, of would a does customers thing meets add,

Operator

We'll with SVB. move Marc next Goodman to

Marc Goodman

price payer I not quarter, know more joined can nets to about up if you're was a average I question sure late, that. this in so for little But probably actually you the on I'm answered contracting and the if you selling I importantly, next gross year. answer finishing curious,

If sense a about year how next give INGREZZA? well ASPs us as you for of into thinking you're can

Matt Abernethy

allow everybody give So the will for for script as script. it's obviously per for terms premature revenue above but we per something as to net would net revenue we a us had give both and net this $X,XXX saw a a per well still expected, bit in of to access everybody a today, have that we're expectation. significant to medicine was ability about to give this us here our going to year progresses. structurally not thinking time, this XXXX, as of price would our see, that change, sitting concern something up or that's to we over Marc, would to we of patients our when And And possible. bit that the cover continue to XXXX rebound heads a insight a lot It's in $X,XXX coverage at as year we guide did lead if revenue of quarter, impact as much to a some script, as

Operator

We'll Amsellem move Sandler. David with next to Piper

David Amsellem

addressed the I the a what's view through this that And past. on extent just you're setting? about to in know maybe mix if could INGREZZA, care over term this, time? your long but you the talked can opportunity the go is an big of contribution getting looking which be portion on you you ahead, how Sorry from

Eric Benevich

our care term So setting. into team long has been deployed very recently that

in of very built that of of otherwise, to We use in there time a that so to confident medicines generate a cause for wouldn't interested recognize the very a very process during capacity homes could force patients nursing We feel about segment there. dedicated because certainly able is in types other This we we really that attracted that have to and we But like we're facilities unfortunately, sales initial issues. in launch. introduce opportunity, to And antipsychotics a planning segment position being care INGREZZA phase care launch and at early were yet were it's in that residential that and the the the TD. business. terms other significant didn't this that of into feel care constraint is

as sales a term really outpatient benefit expand From few our made important is probably the first we And it's we take as right And when we've of focus of perspective, most not well thing. psychiatry tackle the care. and long of large time to so felt a health to decision on and year, meaningful private our from last an reorganize practice represented which clinics, the it's to that neurology that's And mental and can on I've scale segments emphasis opportunity then and there's revisited this. We that the on field as the got an large years for go-to-market patients the movement readiness significant. prioritized disorders, it's as launch. into community other we But team, the with described. number focusing approach and was INGREZZA, our

with our further get not also term provide force. of shaping able I'll be terms our new more sales to focus we with but as care and neurology So color are down expanded just how team road, in things dedicated long up, neurology the in the

So stay tuned.

Operator

Ami We'll move & Fadia to next Company. Needham with

Unidentified Analyst

force some give wondering sales obviously, of This What force was neurology -- of created year? is of the can think [Ameen] for that the if for expansion you impact on remainder business. on Ami. feedbacks side and seeing about you there, dedicated should this the are for how the color the early a I you are we INGREZZA's the sales in

Eric Benevich

into could access And that our focus really, analytics example, well team. with And and We've of that, ONGENTYS the has to Certainly, neurology we been work we XX% for INGREZZA feedback really more. these team XX% positive. a think the And some specialists. in can that for about we've that support the ONGENTYS has movement help team sales to products we that get be case neurology business dedicated INGREZZA. the With for regards did our has to particular, with very it neurology, in of said think got together, neurology that represented a two frankly, meaning, bring they neurology. they can expanding

outside early hired with company. we quarters of from pleased three the very we're team feedback. About the the so And

were but our we smaller neurologists with on So broader And what so speak, learners. previously to set they're still rope, calling than a calling learning we've organization. they're on the quick sales started of

investment, we about really under lot the So neurology old growth we ultimately, early all into positive. opportunity as feel tap a we that very think couldn't And before, structure. there's of I are that signs good the the said in

get So things those across more of later three all segments. really into able are as I'll going next year in a how year, terms and we lot care to in color the be provide of

Operator

with we'll next Yatin And move to Partners. Suneja Guggenheim

Yatin Suneja

-- from would warrant seizure to the from development what terms you you standpoint, study? Could understand XXX. would of a it terms on like the question the efficacy about the in for of study. expectation that talk a dose study see I bigger you adult in product onset to finding have running? a that signal you're further attributes, in focal I is But

Eiry Roberts

going XXX program, Yes, focal have II the excited both we're in in the in two epilepsy disease we very and SCNXA, about Phase programs rare onset epilepsy parallel. on and those

we endpoint adults are frequency And seizures, in dose a the study. is focal approach. the as using finding evaluating seizure [value] the there, that a onset For primary

of study. And primary endpoint end will the at be that so the the

also very to addition next in we've progress. profile from setting study been that molecule the Obviously, to posting dose quality I looking the I data adverse date, data and read But be the order finding at and we tolerability, from event from our data the other the the described, be by whether to not this exposure intend study. year. based around to or the life think, drug at the We obviously of study this sometime of program, measures to to of looking in will this we'll encouraged in that in and are other profile Phase on the II understand out the totality Phase

Operator

And it the to now. looks like end all questions we of the got

I now to to back turn So would Kevin. like things

Kevin Gorman

pipeline investments half that six the reach the to date. to had our thank you, in We've months, be year. expect those today, increase answers continued really second through patient Thank for focus of of INGREZZA and about you year be year, to hope I'm everyone, found significant And first built and you questions. XX population forward to our looking our Chloe. everyone the your the over as to very us our much, to It I'm good We've an very extremely especially to growth half the we the transparent to also get in allowed helpful. and of we've and I progresses. made optimistic

you, the Over months, of XX have next we five To important a programs. pivotal number remind readouts. have we clinical

be Phase coming months. the we're those very we’ll all and in a more seven have Phase talking I And program We about new that of II adding programs. interesting

if Neurocrine many, forward outstanding throughout job looking here. So overall, we the remainder with to you, not challenging year. together And are has is still done all of a what think the environment, I in of an getting

you thank again, your once much So very for attention.

Operator

your for you Thank participation. program. today's conclude does This

a time. Have evening. disconnect at wonderful any may You

Neurocrine Biosciences (NBIX) 5 Aug 222022 Q2 Earnings call transcript